| Literature DB >> 18023944 |
Martin O C Ota1, Roger H Brookes, Philip C Hill, Patrick K Owiafe, Hannah B Ibanga, Simon Donkor, Timothy Awine, Helen McShane, Richard A Adegbola.
Abstract
Understanding the immunogenicity of BCG in a population where it has failed will facilitate the design of new TB vaccines. We assessed the immunogenicity of M. bovis BCG over 12 months by ELISPOT assay. Forty-one adolescents and young Gambian male adults received a tuberculin skin test (TST) which was followed one week later by BCG vaccination, but the 23 control subjects received neither of these. TST alone significantly induced PPD-specific IFN-gamma producing cells. Twenty-three percent of subjects did not respond to BCG, which was associated with higher pre-existing ex vivo response to PPD. Paradoxically, amongst BCG responders there was a correlation between pre-existing response and subsequent response to BCG. We conclude that BCG is immunogenic, but this effector response is short-lived and can be limited in higher pre-existing anti-mycobacterial immunity, suggesting a possible threshold beyond which BCG immunogenicity is inhibited.Entities:
Mesh:
Substances:
Year: 2007 PMID: 18023944 DOI: 10.1016/j.vaccine.2007.10.025
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641